BACKGROUND: Renal toxicity from conventional, iodinated, intravenous contrast agents is a common complication in patients with peripheral artery disease (PAD). Similarly, the potential for serious side effects prevents the use of gadolinium-based agents in many patients with depressed renal function. Ferumoxytol-enhanced magnetic resonance angiography (Fe-MRA) is a novel technique that uses an intravenous, ultrasmall, superparamagnetic, iron oxide preparation, currently approved by the Food and Drug Administration for the treatment of iron deficiency anemia in adults with chronic kidney disease. Our objective was to determine the feasibility of Fe-MRA for clinical decision making in PAD patients. METHODS: This was a prospective pilot study assessing 10 patients with suspected arterial occlusive disease with contrast-enhanced MRA of the aorta and lower extremities. Of those, 5 had renal insufficiency and were imaged with Fe-MRA, whereas the remainder underwent gadolinium-enhanced MRA. Qualitative and quantitative evaluations of deidentified images at each arterial station were independently performed by 4 blinded vascular surgeons. RESULTS: All patients were men, with an average age of 68 ± 4 years. The 2 groups had similar incidences of diabetes, hypertension, hyperlipidemia, and coronary artery disease. Patients undergoing Fe-MRA had significantly decreased renal function (estimated glomerular filtration rate, 35.4 vs. 77.6; P = 0.02). There were no adverse events during contrast administration in either group. No difference was found in the overall quality of the ferumoxytol versus the gadolinium studies (7.1 ± 2.0 vs. 7.4 ± 2.4, P = 0.67). Similarly, reviewers felt comfortable basing clinical decisions on the images 89% of the time with both the ferumoxytol and gadolinium groups (P = 1.00). CONCLUSIONS: This is the first report of an important alternative to conventional computed tomography angiography and MRA in PAD patients, particularly in the setting of renal insufficiency. Fe-MRA provides a useful tool in patients with suspected lower extremity PAD without the potential risks of gadolinium.
BACKGROUND:Renal toxicity from conventional, iodinated, intravenous contrast agents is a common complication in patients with peripheral artery disease (PAD). Similarly, the potential for serious side effects prevents the use of gadolinium-based agents in many patients with depressed renal function. Ferumoxytol-enhanced magnetic resonance angiography (Fe-MRA) is a novel technique that uses an intravenous, ultrasmall, superparamagnetic, iron oxide preparation, currently approved by the Food and Drug Administration for the treatment of iron deficiency anemia in adults with chronic kidney disease. Our objective was to determine the feasibility of Fe-MRA for clinical decision making in PAD patients. METHODS: This was a prospective pilot study assessing 10 patients with suspected arterial occlusive disease with contrast-enhanced MRA of the aorta and lower extremities. Of those, 5 had renal insufficiency and were imaged with Fe-MRA, whereas the remainder underwent gadolinium-enhanced MRA. Qualitative and quantitative evaluations of deidentified images at each arterial station were independently performed by 4 blinded vascular surgeons. RESULTS: Allpatients were men, with an average age of 68 ± 4 years. The 2 groups had similar incidences of diabetes, hypertension, hyperlipidemia, and coronary artery disease. Patients undergoing Fe-MRA had significantly decreased renal function (estimated glomerular filtration rate, 35.4 vs. 77.6; P = 0.02). There were no adverse events during contrast administration in either group. No difference was found in the overall quality of the ferumoxytol versus the gadolinium studies (7.1 ± 2.0 vs. 7.4 ± 2.4, P = 0.67). Similarly, reviewers felt comfortable basing clinical decisions on the images 89% of the time with both the ferumoxytol and gadolinium groups (P = 1.00). CONCLUSIONS: This is the first report of an important alternative to conventional computed tomography angiography and MRA in PAD patients, particularly in the setting of renal insufficiency. Fe-MRA provides a useful tool in patients with suspected lower extremity PAD without the potential risks of gadolinium.
Authors: Robert Provenzano; Brigitte Schiller; Madhumathi Rao; Daniel Coyne; Louis Brenner; Brian J G Pereira Journal: Clin J Am Soc Nephrol Date: 2009-01-28 Impact factor: 8.237
Authors: Martin R Prince; Honglei Zhang; Michael Morris; Jennifer L MacGregor; Marc E Grossman; Jeffrey Silberzweig; Robert L DeLapaz; Henry J Lee; Cynthia M Magro; Anthony M Valeri Journal: Radiology Date: 2008-09 Impact factor: 11.105
Authors: Michael D Hope; Thomas A Hope; Chengcheng Zhu; Farshid Faraji; Henrik Haraldsson; Karen G Ordovas; David Saloner Journal: AJR Am J Roentgenol Date: 2015-06-23 Impact factor: 3.959
Authors: Puja Shahrouki; Kim-Lien Nguyen; John M Moriarty; Adam N Plotnik; Takegawa Yoshida; J Paul Finn Journal: Br J Radiol Date: 2021-09-01 Impact factor: 3.629
Authors: Gerda B Toth; Csanad G Varallyay; Andrea Horvath; Mustafa R Bashir; Peter L Choyke; Heike E Daldrup-Link; Edit Dosa; John Paul Finn; Seymur Gahramanov; Mukesh Harisinghani; Iain Macdougall; Alexander Neuwelt; Shreyas S Vasanawala; Prakash Ambady; Ramon Barajas; Justin S Cetas; Jeremy Ciporen; Thomas J DeLoughery; Nancy D Doolittle; Rongwei Fu; John Grinstead; Alexander R Guimaraes; Bronwyn E Hamilton; Xin Li; Heather L McConnell; Leslie L Muldoon; Gary Nesbit; Joao P Netto; David Petterson; William D Rooney; Daniel Schwartz; Laszlo Szidonya; Edward A Neuwelt Journal: Kidney Int Date: 2017-04-20 Impact factor: 10.612
Authors: Hasan Alsaid; Tinamarie Skedzielewski; Mary V Rambo; Kristen Hunsinger; Bao Hoang; William Fieles; Edward R Long; James Tunstead; Danielle J Vugts; Matthew Cleveland; Neil Clarke; Christopher Matheny; Beat M Jucker Journal: PLoS One Date: 2017-04-27 Impact factor: 3.240
Authors: Kim-Lien Nguyen; Fei Han; Ziwu Zhou; Daniel Z Brunengraber; Ihab Ayad; Daniel S Levi; Gary M Satou; Brian L Reemtsen; Peng Hu; J Paul Finn Journal: J Cardiovasc Magn Reson Date: 2017-04-03 Impact factor: 5.364
Authors: Kim-Lien Nguyen; Takegawa Yoshida; Nikhita Kathuria-Prakash; Islam H Zaki; Csanad G Varallyay; Scott I Semple; Rola Saouaf; Cynthia K Rigsby; Sokratis Stoumpos; Kevin K Whitehead; Lindsay M Griffin; David Saloner; Michael D Hope; Martin R Prince; Mark A Fogel; Mark L Schiebler; Giles H Roditi; Aleksandra Radjenovic; David E Newby; Edward A Neuwelt; Mustafa R Bashir; Peng Hu; J Paul Finn Journal: Radiology Date: 2019-10-22 Impact factor: 11.105